The World Health Organization (WHO) validated the CoronaVac COVID-19 inactivated vaccine for emergency use on June 1, 2021.
This WHO authorization gives countries, funders, procuring agencies, and communities the assurance that the CoronaVac vaccine meets international standards for safety, efficacy, and manufacturing.
CoronaVac is produced by the Beijing-based pharmaceutical company Sinovac.
China COVID-19 Vaccine Authorized by the WHO
Comparative analysis of TOPSIS, VIKOR and COPRAS methods for the COVID-19 Regional Safety Assessment.
COVID-19, which emerged in December 2019, has affected the entire world. Therefore, COVID-19 has been a subject of research in various disciplines, especially in the field of health. One of […]
Clinical evaluation of rapid point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
The RT-qPCR in respiratory specimens is the gold standard for diagnosing acute COVID-19 infections. However, this test takes considerable time before test results become available, thereby delaying patients from being […]
WHO Approves Second Chinese COVID-19 Vaccine
Emergency use authorization based on data showing two doses of Sinovac are about 50 percent effective
Most Severe Effects of PIMS-TS Resolved at Six Months
Findings generally favorable for patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2
ASCO: COVID-19 Infections, Deaths Not Up With Breast Cancer Chemo
Risk for death following SARS-CoV-2 infection increased with advanced-stage disease, higher comorbidity, but not receipt of chemotherapy
Drug-Induced Immunosuppression Examined in U.S. Adults
Drug-induced immunosuppression, particularly from oral corticosteroids, may limit response to COVID-19 vaccine
Delaying Surgery Linked to Worse Outcomes for NSCLC
Risk for recurrence increased with surgical delay beyond 12 weeks; overall survival improved with surgery within 12 weeks
BNT162b2 Vaccine Safe, Effective for Teens Aged 12 to 15 Years
Vaccine efficacy was 100 percent; no cases of COVID-19 with onset of seven or more days after dose 2 seen among BNT162b2 recipients
Asthma Flares Down Among Black, Hispanic Patients During Pandemic
Greatest decrease seen for those previously working outside of the home and in those without ‘allergic-type’ inflammation
- Page 1 of 2
- 1
- 2